The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept after once-weekly subcutaneous administrations of amycretin in 125 people with overweight or obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback